ArticleHeliyon2025
LINE-1 methylation status and survival outcomes in colorectal cancer patients: A systematic review and meta-analysis.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long interspersed nuclear element 1 methylation in non-small cell lung cancer: implications for diagnosis, prognosis, and therapeutic targeting.Cell communication and signaling : CCS · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. DNA hypomethylation, particularly of Long Interspersed Nuclear Element-1 (LINE-1) repetitive sequences, has been implicated in CRC development and progression. The purpose of this meta-analysis and systematic review was to evaluate the prognostic value of LINE-1 methylation level in patients with CRC. Relevant studies were identified through systematic database searches, and summary hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated for relations between LINE-1 hypomethylation and overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS). The current systematic review protocol was registered on International Prospective Register of Systematic Reviews (PROSPERO, CRD42024496615). A total of 19 studies comprising 8169 CRC patients were included. The pooled analysis showed no significant association between LINE-1 hypomethylation and OS in the overall population (HR = 1.70, 95 % CI: 0.97-2.96). However, in stage II/III patients, LINE-1 hypomethylation was significantly associated with poorer OS (HR = 1.92, 95 % CI: 1.26-2.91) and DFS (HR = 2.81, 95 % CI: 1.33-5.93). No significant association was found between LINE-1 hypomethylation and CSS (HR = 1.39, 95 % CI: 0.68-2.83). Substantial heterogeneity was observed across studies. The study suggests that LINE-1 methylation level could be a valuable prognostic biomarker for advanced-stage CRC patients, potentially improving personalized care and highlighting areas for future research to establish standardized methodologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.